{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:55:37Z","timestamp":1791312937844,"version":"4.3.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":3136,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1124\/dmd.115.066845","type":"journal-article","created":{"date-parts":[[2016,3,30]],"date-time":"2016-03-30T01:43:56Z","timestamp":1459302236000},"page":"821-832","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":98,"title":["Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic Model"],"prefix":"10.1016","volume":"44","author":[{"given":"Lisa M.","family":"Almond","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Mukadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystle","family":"Okialda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Hatley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Rowland-Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Jamei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Rostami-Hodjegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane R.","family":"Kenny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.115.066845_bib1","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1159\/000220750","article-title":"Kinetic studies on rifampicin. I. Serum concentration analysis in subjects treated with different oral doses over a period of two weeks","volume":"16","author":"Acocella","year":"1971","journal-title":"Chemotherapy"},{"key":"10.1124\/dmd.115.066845_bib2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/0091270004271969","article-title":"Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways","volume":"45","author":"Adams","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.115.066845_bib3","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2174\/138920009788498978","article-title":"Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction","volume":"10","author":"Almond","year":"2009","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.115.066845_bib4","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1528-1167.2007.00924.x","article-title":"A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on cyp3a4","volume":"48","author":"Andreasen","year":"2007","journal-title":"Epilepsia"},{"key":"10.1124\/dmd.115.066845_bib5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s002280050420","article-title":"The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin","volume":"54","author":"Backman","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.115.066845_bib6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0009-9236(96)90018-1","article-title":"Rifampin drastically reduces plasma concentrations and effects of oral midazolam","volume":"59","author":"Backman","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.115.066845_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejps.2014.02.002","article-title":"Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration","volume":"56","author":"Baneyx","year":"2014","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/dmd.115.066845_bib8","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s40262-013-0089-y","article-title":"Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling","volume":"52","author":"Barter","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.115.066845_bib9","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.clpt.2005.11.016","article-title":"Comparison of midazolam and simvastatin as cytochrome P450 3A probes","volume":"79","author":"Chung","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.115.066845_bib10","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3109\/00498254.2011.560294","article-title":"Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model","volume":"41","author":"Cubitt","year":"2011","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.115.066845_bib11","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJM197603252941305","article-title":"Interaction of quinidine with anticonvulsant drugs","volume":"294","author":"Data","year":"1976","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.115.066845_bib12","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/jcph.79","article-title":"Time-dependent inhibition and induction of human cytochrome P4503A4\/5 by an oral IAP antagonist, LCL161, in vitro and in vivo in healthy subjects","volume":"53","author":"Dhuria","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.115.066845_bib13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1128\/AAC.30.1.42","article-title":"Steady-state serum pharmacokinetics of novobiocin and rifampin alone and in combination","volume":"30","author":"Drusano","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.115.066845_bib14","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00228-004-0762-z","article-title":"Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity","volume":"60","author":"Eap","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.115.066845_bib15","first-page":"1257","article-title":"Comparison of different approaches to predict metabolic drug-drug interactions","volume":"37","author":"Einolf","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.115.066845_bib16","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/clpt.2013.170","article-title":"Evaluation of various static and dynamic modeling methods to predict clinical CYP3A induction using in vitro CYP3A4 mRNA induction data","volume":"95","author":"Einolf","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.115.066845_bib17","series-title":"Guideline on the Investigation of Drug Interactions","year":"2012"},{"key":"10.1124\/dmd.115.066845_bib18","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1124\/dmd.108.026252","article-title":"Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction","volume":"37","author":"Fahmi","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.066845_bib19","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1124\/dmd.107.018663","article-title":"A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro","volume":"36","author":"Fahmi","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.066845_bib20","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/00008571-200310000-00003","article-title":"Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women","volume":"13","author":"Floyd","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.115.066845_bib21","series-title":"Guidance for Industry: Drug Interactions Studies\u2014Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations","year":"2012"},{"key":"10.1124\/dmd.115.066845_bib22","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/0091270010366445","article-title":"Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism","volume":"51","author":"Gandelman","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.115.066845_bib23","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2165\/11594420-000000000-00000","article-title":"Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance","volume":"50","author":"Ghobadi","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.115.066845_bib24","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0009-9236(03)00187-5","article-title":"The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity","volume":"74","author":"Gorski","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.115.066845_bib25","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.ejps.2013.06.009","article-title":"Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions","volume":"49","author":"Greupink","year":"2013","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/dmd.115.066845_bib26","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1124\/dmd.110.036103","article-title":"Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions","volume":"39","author":"Guest","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.066845_bib27","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/0091270005284854","article-title":"Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin","volume":"46","author":"Gurley","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.115.066845_bib28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/sj.clpt.6100222","article-title":"Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo","volume":"83","author":"Gurley","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.115.066845_bib29","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.vascn.2012.07.004","article-title":"An \u2018all-inclusive\u2019 96-well cytochrome P450 induction method: measuring enzyme activity, mRNA levels, protein levels, and cytotoxicity from one well using cryopreserved human hepatocytes","volume":"66","author":"Halladay","year":"2012","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1124\/dmd.115.066845_bib30","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0090-9556(25)08415-6","article-title":"The nifedipine-rifampin interaction: evidence for induction of gut wall metabolism","volume":"24","author":"Holtbecker","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.066845_bib31","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1002\/jps.23570","article-title":"The utility of modeling and simulation in drug development and regulatory review","volume":"102","author":"Huang","year":"2013","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.115.066845_bib32","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2133\/dmpk.24.53","volume":"24","author":"Jamei","year":"2009","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.115.066845_bib33","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00000542-199707000-00006","article-title":"The role of cytochrome P450 3A4 in alfentanil clearance: implications for interindividual variability in disposition and perioperative drug interactions","volume":"87","author":"Kharasch","year":"1997","journal-title":"Anesthesiology"},{"key":"10.1124\/dmd.115.066845_bib34","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/clpt.2010.313","article-title":"Concurrent assessment of hepatic and intestinal cytochrome P450 3A activities using deuterated alfentanil","volume":"89","author":"Kharasch","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.115.066845_bib35","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.clpt.2004.07.006","article-title":"Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis","volume":"76","author":"Kharasch","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.115.066845_bib36","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1067\/mcp.2000.111414","article-title":"Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations","volume":"68","author":"Kyrklund","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.115.066845_bib37","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2125.2008.03201.x","article-title":"Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping","volume":"66","author":"Link","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.115.066845_bib38","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1124\/dmd.30.7.795","article-title":"CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes","volume":"30","author":"Luo","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.066845_bib39","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/sj.bjp.0707601","article-title":"Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells","volume":"153","author":"Martin","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1124\/dmd.115.066845_bib40","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1124\/dmd.109.026526","article-title":"Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cells","volume":"37","author":"McGinnity","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.066845_bib41","first-page":"505","article-title":"A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans","volume":"70","author":"Phimmasone","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.115.066845_bib42","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/clpt.2010.271","article-title":"Rifampin\u2019s acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design","volume":"89","author":"Reitman","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.115.066845_bib43","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/bdd.1776","article-title":"Physiologically based pharmacokinetic (PBPK) modeling: it is here to stay!","volume":"33","author":"Rostami-Hodjegan","year":"2012","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.115.066845_bib44","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ejps.2009.12.002","volume":"39","author":"Rowland Yeo","year":"2010","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/dmd.115.066845_bib45","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/S0022-3565(25)23442-5","article-title":"Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a \u201ccocktail\u201d study design","volume":"249","author":"Schellens","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.115.066845_bib46","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/01213011-199912000-00007","article-title":"Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine","volume":"9","author":"Schmider","year":"1999","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.115.066845_bib47","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.bbalip.2007.04.012","article-title":"Rifampicin-induced CYP3A4 activation in CTX patients cannot replace chenodeoxycholic acid treatment","volume":"1771","author":"Szalat","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/dmd.115.066845_bib48","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1177\/009127009903900508","article-title":"Morning spot and 24-hour urinary 6 beta-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP 3A4 induction","volume":"39","author":"Tran","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.115.066845_bib49","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00228-003-0700-5","article-title":"Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid","volume":"59","author":"Ucar","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.115.066845_bib50","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0009-9236(97)90176-4","article-title":"Triazolam is ineffective in patients taking rifampin","volume":"61","author":"Villikka","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.115.066845_bib51","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0009-9236(97)90082-5","article-title":"Rifampin reduces plasma concentrations and effects of zolpidem","volume":"62","author":"Villikka","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.115.066845_bib52","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1177\/0091270010383690","article-title":"Pharmacokinetic interaction between zolpidem and carbamazepine in healthy volunteers","volume":"51","author":"Vlase","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.115.066845_bib53","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40262-015-0330-y","article-title":"Predicting the Effect of CYP3A Inducers on the Pharmacokinetics of Substrate Drugs Using Physiologically Based Pharmacokinetic (PBPK) Modeling: An Analysis of PBPK Submissions to the US FDA","volume":"55","author":"Wagner","year":"2016","journal-title":"Clin Pharmacokinet 2016"},{"key":"10.1124\/dmd.115.066845_bib54","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/pmic.201000456","article-title":"Quantitative protein determination for CYP induction via LC-MS\/MS","volume":"11","author":"Williamson","year":"2011","journal-title":"Proteomics"},{"key":"10.1124\/dmd.115.066845_bib55","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejps.2014.06.021","article-title":"Physiologically based pharmacokinetic modeling for assessing the clinical drug-drug interaction of alisporivir","volume":"63","author":"Xia","year":"2014","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/dmd.115.066845_bib56","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1124\/dmd.111.038067","article-title":"Simulation of clinical drug-drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs","volume":"39","author":"Xu","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.066845_bib59","doi-asserted-by":"crossref","first-page":"676","DOI":"10.2174\/138920007782109733","article-title":"Prediction of intestinal first-pass drug metabolism","volume":"8","author":"Yang","year":"2007","journal-title":"Current Drug Metabolism"},{"key":"10.1124\/dmd.115.066845_bib57","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2174\/138920008784746382","article-title":"Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions","volume":"9","author":"Yang","year":"2008","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.115.066845_bib58","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/clpt.2012.68","article-title":"Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions","volume":"92","author":"Zhao","year":"2012","journal-title":"Clin Pharmacol Ther"}],"updated-by":[{"DOI":"10.1124\/dmd.115.066845err","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000}}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624100219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624100219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.115.066845","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T19:18:29Z","timestamp":1739906309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624100219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0090955624100219"],"URL":"https:\/\/doi.org\/10.1124\/dmd.115.066845","relation":{"erratum":[{"id-type":"doi","id":"10.1124\/dmd.115.066845err","asserted-by":"object"}]},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic Model","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.115.066845","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}